Patent classifications
C07D407/14
Fused imidazole derivatives as IL-17 modulators
A series of substituted fused bicyclic imidazole derivatives, including benzimidazole derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
Fused imidazole derivatives as IL-17 modulators
A series of substituted fused bicyclic imidazole derivatives, including benzimidazole derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
Pyrazole derivatives for the treatment of cystic fibrosis
The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities. ##STR00001##
Mannose derivatives for treating bacterial infections
The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: ##STR00001## The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.
Mannose derivatives for treating bacterial infections
The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: ##STR00001## The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.
Heterocyclic compound and organic light-emitting element including same
Provided is a hetero-cyclic compound of Chemical Formula 1: ##STR00001##
and an organic light emitting device comprising the same.
Heterocyclic compound and organic light-emitting element including same
Provided is a hetero-cyclic compound of Chemical Formula 1: ##STR00001##
and an organic light emitting device comprising the same.
3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
The present disclosure provides a compound of Formula (I′):
##STR00001## or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R.sub.x, X.sub.1, X.sub.2, and R.sub.1 are as defined herein, and methods of making and using same.
3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
The present disclosure provides a compound of Formula (I′):
##STR00001## or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R.sub.x, X.sub.1, X.sub.2, and R.sub.1 are as defined herein, and methods of making and using same.
QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS
The present invention relates to a compounds of general formula (I) inhibiting lysophosphatidic acid receptor 2 (LPA2), particularly the invention relates to compounds that are quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.